Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
about
Bisphosphonates for preventing and treating osteoporosis in menInterventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophyIntravenous zoledronate for postmenopausal osteoporosisEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceOnce-yearly zoledronic acid in hip fracture preventionIntravenous zoledronate for osteoporosis: less might be moreSurgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature reviewThe Relationship between Metabolic Syndrome and Osteoporosis: A ReviewBisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysisMicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for OsteoporosisPrevention and treatment of bone fragility in cancer patientClodronate: new directions of useEmerging Therapies for OsteoporosisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchCalcium intake and bone mineral density: systematic review and meta-analysisDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsThe evolution of selective estrogen receptor modulators in osteoporosis therapyThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceOsteoporosis Treatment: When to Discontinue and When to Re-startTreatment of primary osteoporosis in menScreening, diagnosis and treatment of osteoporosis: a brief reviewBisphosphonate drug holiday: choosing appropriate candidatesEpidemiology and management of osteoporosis in the People's Republic of China: current perspectivesDenosumab for the treatment of osteoporosisAn overview on the treatment of postmenopausal osteoporosisDenosumab: mechanism of action and clinical outcomesDo bisphosphonates cause femoral insufficiency fractures?A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major TraumaBone anabolics in osteoporosis: Actuality and perspectivesAtypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and PreventionThe epidemiology and management of postmenopausal osteoporosis: a viewpoint from BrazilIncreasing options for the treatment of osteoporosisBreast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled TrialsEffectiveness of a minimal resource fracture liaison serviceReactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cellsRecent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblastsOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.
P2860
Q24197612-83411F76-340E-4B2F-B348-E6A4ADEE6260Q24198280-A74579D1-DEBF-430C-B88E-1C30B659788FQ24239823-126DD01E-9837-479D-BF13-DF455365A810Q24612411-D8B9339E-29BC-432D-976F-693DFCDF11D7Q24644708-62A434A0-7D19-4F3D-A1F5-931BE8A98180Q24657667-98737373-9B29-4622-94E8-A1E4DEE2E590Q26738958-A53FCE29-D693-4F45-98A6-1E66A4DDAD0DQ26744057-8D548379-10E8-4B8E-A537-0F3D42A75F68Q26747451-9C7256DB-5121-4ECB-B8A7-2C1FF20935D5Q26749442-AAAFFEF6-D47F-4DD4-9FC4-F064939FFEB4Q26752588-C9981FA6-A077-4BBC-B698-70174FAB9609Q26775765-AC4AC76C-34CB-424D-B233-9B387E97F27DQ26775773-45676B9A-65B5-4D97-9B40-D18227243F83Q26782109-2609FE09-719D-4680-9F93-18FB9BA34E32Q26782621-4DBA104C-0288-4CD1-B2DD-EA9AD7EAAFEEQ26784337-C0B5B4B4-281C-4414-B407-EADE31601DB9Q26824762-99567998-3908-4002-A9D8-9315B696E7E9Q26827973-09B168D8-EAE6-4E47-B4AD-FA755FB8F990Q26830744-6899E872-B369-439E-8F52-10390C61AD2CQ26858980-CDB55936-DFE3-4392-AFC7-15D7807E4996Q26991748-DD8C8AA9-FD4F-4F5B-B87E-BD4BF6D4667AQ26996726-B69F7784-0961-4CB8-B2F4-171B695FEB84Q27004682-596B7845-C2AC-4326-A27C-6F7470AA5D4EQ27005978-5A856981-30A7-467A-991E-E46C1938A7C4Q27009275-54006396-5501-4E44-A603-8F47D76AF972Q27013070-2211D585-9D89-4897-9891-BC1E6D945312Q27015899-0DB7F03F-BB87-458F-AAD1-1E56BC1E62E7Q27021396-DE0348E9-D61B-4EAC-B419-F9ED42ECCFBEQ27302911-8DC41B7B-E365-47B5-947F-D1C0490FC1B2Q27691122-FDB6B7B1-3FBE-46AA-BF0A-785B99FB1B7CQ28079133-C19C5702-7C0F-44B1-8DC2-1D8EDF7A0F65Q28080673-FE199488-7925-400F-8919-06FD267CA9F3Q28254516-6C4388A2-24D1-4A06-9D88-F0D257913830Q28269986-3D1413D7-E218-426E-B5D8-A8ECB33BA22DQ28391373-9746EDA3-0B4D-4F1D-9BBE-C9DF25409F9CQ28540022-B65ACB01-3104-40A9-BB73-100254C6586AQ28540086-F6655216-4D01-48A7-AE33-F6FAEFD976BDQ28552191-EF0AC98B-789B-4F8A-B846-9FAE35006225Q28569888-E6F2CD9D-A712-4A17-9BC8-4DADA22F6CACQ30235173-844B0343-A049-4A75-88FF-D3D9DEEF9BB0
P2860
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@ast
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@en
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@nl
type
label
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@ast
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@en
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@nl
prefLabel
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@ast
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@en
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@nl
P2093
P356
P1476
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
@en
P2093
Carlos Mautalen
Deborah Sellmeyer
Dennis M Black
Erik Fink Eriksen
Felicia Cosman
HORIZON Pivotal Fracture Trial
Joel Krasnow
John Caminis
Karen Tong
P304
P356
10.1056/NEJMOA067312
P407
P577
2007-05-01T00:00:00Z